GCB helps spin out success

GCB logo, no words
GCB News

GCB helps spin out success

In FY20, 17 new start-up companies formed at Duke, according to Duke’s Office of Licensing and Ventures (OLV).

Xilis is headed by GCB members David Hsu, M.D, Ph.D. and Xiling Shen, Ph.D. The company is developing next-generation micro-organosphere technology to guide precision therapy for cancer patients and accelerate drug discovery.

The Proteomics and Metabolomics Core Facility have provided their services to several of the PIs who spun out companies in FY 20 as well. 

OLV oversees the management of innovations resulting from Duke research – from creation, to feasibility and marketing, to protection, and on into licensing to commercial partners, for both startups and existing companies.

Read OLV’s Annual Report for more information

Related News

‘Swarmbots,’ living cells engineered to produce monomer molecules, grow until they sense their population density has reached a certain level, whereupon they burst open, allowing the monomers to mingle and self-assemble into a composite polymer.

Cells Construct Living Composite Polymers for Biomedical Applications

Initial demonstration builds drug delivery system that protects the gut microbiome from antibiotics
Children jumping rope

Joining Forces to Fight Childhood Obesity

Today, nearly one in three kids is overweight or has obesity.
8 headshots and Summer Scholars logo

2021 Summer Scholars Program welcomes new recruits

The 2021 Summer Scholars Program in Genome Sciences and Medicine for Underrepresented Minority Underclassmen begins May 11 and will run t